Vertex Pharmaceuticals demonstrates resilience with robust CF franchise, new approvals, and diversification efforts. Read why ...

Vertex Pharma receives CHMP positive opinion for label expansion of Kaftrio in combination with ivacaftor: London Tuesday, March 4, 2025, 14:00 Hrs [IST] Vertex Pharmaceuticals, a ...

Vertex Pharmaceuticals (VRTX) stock in focus as company secures EU backing to expand label for its cystic fibrosis therapy ...

The committee supports approving the CFTR modulator for patients 2 years and older with at least one non-class I CFTR gene mutation.

Members of the International Hearing Society (IHS) are gearing up to celebrate World Hearing Day on March 3, 2025, to raise awareness of hearing healthcare and address the stigma attached to hearing ...

Vertex Pharmaceuticals (VRTX) announced that the European Medicines Agency’s Committee for Medicinal Products for Human Use adopted an opinion ...

Cystic Fibrosis (CF) is an incurable, life-limiting condition, affecting over 11,300 people in the UK costing the NHS millions in care.

The pharma industry is delivering game-changing therapies with favorable regulatory support. Amid this backdrop, investors ...

A new inhalable gene therapy for cystic fibrosis (CF) has entered Phase I clinical trials, a major milestone on the journey ...

Vertex markets all of them. Its top product, Trikafta/Kaftrio, raked in sales of $10.2 billion last year. The company won U.S ...

Its key drugs are Kalydeco, Orkambi, Symdeko, and Trikafta/Kaftrio for cystic fibrosis, where Vertex therapies remain the standard of care globally. Vertex has diversified its portfolio through ...

NEW YORK – Boehringer Ingelheim on Wednesday said the US Food and Drug Administration accepted its new drug application for the irreversible tyrosine kinase inhibitor zongertinib as a treatment for ...